134067-56-4

Basic information

• Product Name: (4aR,4bS,6aS,7S,9aS,9bS,11aR)-7-benzoyl-4a,6a-dimethyl-1,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-2H-indeno[5,4-f]quinolin-2-one
• CAS NO: 134067-56-4
• Molecular Formula: C₂₅H₃₁NO₂
• Molecular Weight: 377.5191
• Mol File: 134067-56-4.mol

Chemical Properties

• Boiling Point: 557°C at 760 mmHg
• Flash Point: 171.2°C
• Density: 1.12g/cm³
• Vapor Pressure: 1.93E-12mmHg at 25°C
• Refractive Index: 1.565
• CAS DataBase Reference: (4aR,4bS,6aS,7S,9aS,9bS,11aR)-7-benzoyl-4a,6a-dimethyl-1,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-2H-indeno[5,4-f]quinolin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: (4aR,4bS,6aS,7S,9aS,9bS,11aR)-7-benzoyl-4a,6a-dimethyl-1,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-2H-indeno[5,4-f]quinolin-2-one(134067-56-4)
• EPA Substance Registry System: (4aR,4bS,6aS,7S,9aS,9bS,11aR)-7-benzoyl-4a,6a-dimethyl-1,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-2H-indeno[5,4-f]quinolin-2-one(134067-56-4)

Safety Data

• Hazardous Substances Data: 134067-56-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
(4aR,4bS,6aS,7S,9aS,9bS,11aR)-7-benzoyl-4a,6a-dimethyl-1,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-2H-indeno[5,4-f]quinolin-2-one is used as a research compound for exploring its potential applications in the pharmaceutical industry. Its unique chemical structure may offer novel insights and opportunities for drug development.
Used in Drug Development:
(4aR,4bS,6aS,7S,9aS,9bS,11aR)-7-benzoyl-4a,6a-dimethyl-1,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-2H-indeno[5,4-f]quinolin-2-one is also used in the development of new drugs, particularly those targeting specific biological pathways or diseases. Its complex structure may provide a foundation for the creation of new therapeutic agents with improved efficacy and selectivity.
Used in Industrial Applications:
(4aR,4bS,6aS,7S,9aS,9bS,11aR)-7-benzoyl-4a,6a-dimethyl-1,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-2H-indeno[5,4-f]quinolin-2-one may find use in various industrial applications, such as the synthesis of other complex organic compounds or as an intermediate in the production of specialty chemicals. Its specific role and utility in these applications would depend on further research and development.

Upstream product

• 100-59-4 phenylmagnesium chloride 
• 138689-15-3 (5α,17β)-N-Methoxy-N-methyl-3-oxo-4-aza-androst-1-ene-17β-carboxamide 
• 103335-49-5 S-2-Pyridyl 3-oxo-4-aza-5alpha-androst-1-ene-17beta-thiocarboxylate 

Relevant articles and documents

A new general method for preparation of N-methoxy-N-methylamides. Application in direct conversion of an ester to a ketone

The reaction of an ester with N,O-dimethylhydroxylamine and a suitable organomagnesium reagent or lithium amide base provides a general method for the preparation of N-methoxy-N-methylamides. Application in the direct conversion of a highly hindered ester to a ketone, the azasteroid 5α-reductase inhibitor MK-0434, is described.

Method of treatment for prostatic cancer

Disclosed is a new treatment for men with prostatic cancer involving combination therapy of a 5α-reductase inhibitor, i.e., a 17β-substituted 4-azasteroid, a 17β-substituted non-azasteroid, 17β-acyl-3-carboxyandrost-3,5-diene, benzoylaminophenoxybutanoic acid derivative, fused benz(thio)amide or cinnamoylamide derivative, aromatic 1,2-diethers or thioethers, aromatic ortho acylaminophenoxy alkanoic acids, ortho thioalkylacylamino-phenoxy alkanoic acids, pharmaceutically acceptable salts and esters thereof, and particularly finasteride, in combination with an antiandrogen, i.e. flutamide. Pharmaceutical compositions useful for treatment are also disclosed.

Method of treatment for benign prostatic hyperplasia

Disclosed is an improved treatment for men with benign prostatic hyperplasia (BPH), involving combination therapy of a 5α-reductase inhibitor, e.g. a 17β-substituted 4-azasteroid, a 17β-substituted non-azasteroid, 17β-acyl-3-carboxy-androst-3,5-diene, benzoylaminophenoxybutanoic acid derivative, fused benz(thio)amide or cinnamoylamide derivative, aromatic 1,2-diethers or thioethers, aromatic ortho acylaminophenoxy alkanoic acids, ortho thioalkylacylaminophenoxy alkanoic acids, pharmaceutically acceptable salts and esters thereof, and particularly finasteride, in combination with an α1 -adrenergic receptor blocker, i.e., terazosin. The combination provides therapy at the molecular level for the underlying cause of the disease as well as providing symptomatic relief. Pharmaceutical compositions useful for treatment are also disclosed.

7β-substituted-4-aza-5α-androstan-3-ones as 5α-reductase inhibitors

Described are new 7β-substituted 4-aza-5α-androstan-3-ones and related compounds as 5α-reductase inhibitors.

Substituted 4-aza-5α-androstan-ones as 5α-reductase inhibitors

Described are new 16-substituted and 7,16-disubstituted 4-aza-5α-androstan-3-ones and related compounds as 5α-reductase inhibitors.

Use of 17beta-acyl-4-aza-5alpha-androst-1-en-3-ones for the preparation of a medicament for the prevention of prostatic carcinoma

17 beta -Acyl-4-aza-5 alpha -androst-1-ene-3-ones of the formula: wherein R is selected from hydrogen, methyl and ethyl and R is monocyclic aryl optionally containing 1 or more lower alkyl substituents of from 1-2 carbon atoms and/or 1 or more halo (Cl o

17β-acyl-4-aza-5α-androst-1-ene-3-ones as 5α-reductase inhibitors

17β-Acyl-4-aza-5α-androst-1-ene-3-ones of the formula STR1 wherein R is selected from hydrogen, methyl and ethyl and R2 is monocyclic aryl optionally containing 1 or more lower alkyl substituents of from 1-2 carbon atoms and/or 1 or more halo (